Single-dose and steady-state effects of controlled-release salbutamol on drug level and airflow obstruction in patients with asthma.
Oral medication remains the mainstay of treatment for many asthmatics. We compared the single dose and steady-state effects of twice daily 4 mg and 8 mg controlled-release salbutamol (CRS) on plasma salbutamol and FEV1 in 10 asthmatic patients in a double-blind, double-dummy, cross-over study. On 5 separate days, one week apart, we measured FEV1 and plasma salbutamol hourly for 12 hours after a single dose and, after twice daily doses (4 mg, 8 mg or placebo CRS) for one week. Controlled-release salbutamol showed controlled release properties and dose effect for the two doses. At steady-state, it provided relatively constant plasma levels for 12 hours. Significant and similar bronchodilatation occurred after both 4 mg and 8 mg CRS taken either as a single dose or a steady-state regime.
Tan
W C
WC
Department of Medicine, National University Hospital, Singapore.
Chan
T B
TB
Ang
S M
SM
D000293:Adolescent; D000328:Adult; D000420:Albuterol / Q000008:administration & dosage* / Q000493:pharmacokinetics; D001249:Asthma / Q000097:blood / Q000188:drug therapy*; D003692:Delayed-Action Preparations; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D005541:Forced Expiratory Volume / Q000187:drug effects; D006801:Humans; D008173:Lung Diseases, Obstructive / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
D003692:Delayed-Action Preparations; D000420:Albuterol